Dermatology Daily Report: 01/24/2024

Atopic Dermatitis

A phase III double-blind, placebo-controlled study investigated the effect of dupilumab in 162 patients with moderate-to-severe atopic dermatitis and found that treatment with dupilumab does not increase the overall risk of infections and is associated with a reduced risk of bacterial and non-herpetic skin infections compared with placebo, leading to a significantly lower use of systemic anti-infective medication (1). The study, LIBERTY AD PRESCHOOL, demonstrated significant reductions in non-herpetic skin infections (RR 0.46, p=0.047) and bacterial infections (RR 0.09, p=0.019), with no significant differences in herpetic infections between the dupilumab and placebo groups.

Reference

Voissière A, Gomez-Roca C, Chabaud S, Rodriguez C, Nkodia A, Berthet J, Montane L, Bidaux AS, Treilleux I, Eberst L, Terret C, Korakis I, Garin G, Pérol D, Delord JP, Caux C, Dubois B, Ménétrier-Caux C, Bendriss-Vermare N, Cassier PA. The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers. Sci Transl Med. 2024 Jan 24;16(731):eadd1834. doi: 10.1126/scitranslmed.add1834. Epub 2024 Jan 24. PMID: 38266104.

Psoriasis

An open-label, single-arm, phase 3 study investigated the effect of deucravacitinib in 74 Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis and found that 76.2% of patients with plaque psoriasis, 66.7% with generalized pustular psoriasis, and 37.5% with erythrodermic psoriasis achieved a ≥75% reduction from baseline in the Psoriasis Area and Severity Index (PASI 75) at week 16 (1). Additionally, 82.5% of patients with plaque psoriasis achieved a static Physician's Global Assessment score of 0 or 1. The study, POETYK PSO-4, demonstrated that deucravacitinib was effective and well-tolerated, with low rates of serious adverse events.

Reference

Imafuku S, Okubo Y, Tada Y, Ohtsuki M, Colston E, Napoli A, Shao Y, Banerjee S, Morita A. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: Efficacy and safety results from an open-label, phase 3 trial. J Dermatol. 2024 Jan 24. doi: 10.1111/1346-8138.17074. Epub ahead of print. PMID: 38268101.